Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Oncologists Face Economic Challenges while Improving Patient Care
Practice Management
,
Value Peer-spectives
July 2011, Vol 2, No 4
The estimated cost for physician practices to interact with health insurance plans is $23 billion to $31 billion annually, according to a 2009 national survey conducted by Casalino and colleagues (Health Aff. 2009;28:w533-w543).
Read More
The Crisis in Cancer Care
By
Ted Okon, MBA
Cancer Care
,
Community Oncology
,
Personalized Medicine
July 2011, Vol 2, No 4
Read More
Community Oncology Clinics under Increasing Financial Pressure
By
Wayne Kuznar
Community Oncology
,
Economics & Value
July 2011, Vol 2, No 4
Changes in oncology reimbursement have driven the consolidation of community oncology practices, as more of these practices are being squeezed financially, according to Ted Okon, BS, MBA, Executive Director, Community Oncology Alliance. Consoli dation decreases alternatives, and that means reduced competition, as many oncologists lose their practices.
Read More
A New Option for Metastatic Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
July 2011, Vol 2, No 4
Philadelphia, PA—The new biologic therapy eribulin (Halaven) was recently approved by the US Food and Drug Administration for the treatment of patients with metastatic breast cancer. Stephen C. Malamud, MD, Attending Physician, Beth Israel Medical Center, New York City, discussed the benefits and risks associated with this new treatment option at a special session during the meeting.
Read More
The Age of Personalized Oncology Therapies
By
Wayne Kuznar
Personalized Medicine
July 2011, Vol 2, No 4
Philadelphia, PA—The age of personalized cancer therapies is upon us. In oncology, personalized medicine encompasses the use of tests to determine the genes and gene interactions that can reliably predict an individual’s response to therapy or the chance of disease recurrence.
Read More
Evidence-Based Practice Should Drive Patient Care
NCCN Guidelines
,
Policies & Guidelines
July 2011, Vol 2, No 4
Read More
NCCN Guidelines Inform Decisions Across the Continuum of Cancer Care
By
Wayne Kuznar
NCCN Guidelines
,
Policies & Guidelines
July 2011, Vol 2, No 4
Philadelphia, PA—The National Com - prehensive Cancer Network (NCCN) is an alliance of academic cancer centers in the United States that seeks to optimize decision-making and policies for improving the delivery of appropriate and effective cancer care.
Read More
Benefit Design Trends in Oncology Management
By
Wayne Kuznar
Oncology Benefit Edition
July 2011, Vol 2, No 4
Read More
The Role of Molecular Diagnostics in Cancer Treatment
By
Wayne Kuznar
Cancer Care
,
Personalized Medicine
July 2011, Vol 2, No 4
Philadelphia, PA—The field of oncology stands to benefit greatly from molecular diagnostic trends, according to Jane F. Barlow, MD, MPH, MBA, Vice President, Clinical Innovation, Medco Health Solutions, who offered a pharmacy benefit manager’s (PBM) perspective of the role of diagnostics, including the use of companion tests in drug development. These companion tests will represent another potential expenditure and coverage decision for PBM companies.
Read More
Payer Trends in Oncology: Challenges and Solutions
By
Wayne Kuznar
July 2011, Vol 2, No 4
Philadelphia, PA—As the cost of cancer care continues to rise, payers are struggling with solutions to curtail the cost trend while maintaining value. This was the topic of the preconference session, which opened the 2-day First Annual Conference of the Association for Value-Based Cancer Care on March 29, 2011.
Read More
Page 313 of 329
310
311
312
313
314
315
316
Top Trending Articles
1.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
2.
From Chaos to Clarity: Data-Driven Denial Prevention
Shawntea (Taya) Gordon, MBA, FACMPE
3.
The Evolving Landscape of Lung Cancer Care
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma